SynCore Biotechnology Co

SynCore Biotechnology Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of SynCore Biotechnology Co (4192.TWO) as of Nov 11, 2026 is 83.78 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 90.71 % — a change of -7.64% (lower).

Cash Conversion

83.78 %

YoY

-7.64%

Last updated:

Cash Conversion Rate (OCF/Net Income) of SynCore Biotechnology Co is 2025 83.78 % . Cash Conversion Rate (OCF/Net Income) of SynCore Biotechnology Co was 2024 90.71 % . It decreases by -7.64% lower compared to the previous year.

The SynCore Biotechnology Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
92.57 TWD
Jan 1, 2019
102.43 TWD
Jan 1, 2020
79.37 TWD
Jan 1, 2021
50.12 TWD
Jan 1, 2022
111.10 TWD
Jan 1, 2023
215.79 TWD
Jan 1, 2024
90.71 TWD
Jan 1, 2025
83.78 TWD
The SynCore Biotechnology Co Cash Conversion history
YEARCash ConversionYoY
83.78 %-7.64%
90.71 %-57.96%
215.79 %+94.23%
111.10 %+121.66%
50.12 %-36.85%
79.37 %-22.51%
102.43 %+10.66%
92.57 %+18.25%
78.28 %-34.90%
120.25 %+40.38%
85.66 %-17.88%
104.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SynCore Biotechnology Co Stock analysis

What does SynCore Biotechnology Co do? SynCore Biotechnology Co Ltd, based in Dongshan, Yilan, Taiwan, operates in the Health Care sector with a focus on Pharmaceuticals. The company develops new drugs and integrates technology, employing 50 full-time staff. Its main product is SB03 Veregen, alongside research and development of anticancer drugs SB01 (injection and oral forms). SynCore primarily distributes its products within Taiwan. SynCore Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SynCore Biotechnology Co stock

Cash Conversion Rate (OCF/Net Income) of SynCore Biotechnology Co is 83.78 % in 2025.

Cash Conversion Rate (OCF/Net Income) of SynCore Biotechnology Co changed from 90.71 % to 83.78 %, representing a -7.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) SynCore Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s SynCore Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — SynCore Biotechnology Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — SynCore Biotechnology Co